The VIKTORY is the first and largest platform umbrella study with 10 phase II trials, the first and most extensive study of multiple biomarker screening-guided targeted therapy in gastric cancer, which showed that the efficacy of savolitinib monotherapy in MET-amplified gastric cancer was significantly better than conventional therapy (6-week PFS rate of 80%).[9] Furthermore, circulating tumor DNA (ctDNA) MET gene copy numbers (GCN) can predict the efficacy of savolitinib. This evidence concerns the gene MET and gastric cancer.